NCT03913715 is a NA clinical trial of Ostomy Self-Management Training in Ostomy, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT03913715?

NCT03913715 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT03913715?

Interventions in NCT03913715: Ostomy Self-Management Training.

What condition does NCT03913715 study?

NCT03913715 studies Ostomy, Quality of Life, Telehealth.

Is NCT03913715 still recruiting?

NCT03913715 is currently active, enrolled. Last updated 11 July 2025.

Last reviewed 2025-07-11 · How we verify

NCT03913715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ostomy Rural Telehealth Training Cancer Survivors

Active, enrolled NA Last updated 11 July 2025

What this trial tests

NA trial testing Ostomy Self-Management Training in Ostomy in 204 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2019

Primary endpoint
1 September 2025

31 October 2026

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	204
Start date	1 August 2019
Primary completion	1 September 2025
Estimated completion	31 October 2026
Sites	10 locations across United States

Drugs / interventions tested

Ostomy Self-Management Training

Conditions studied

Ostomy — all drugs for Ostomy →
Quality of Life — all drugs for Quality of Life →
Telehealth — all drugs for Telehealth →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

Adults 18 to 120, any sex, with Ostomy or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Over one million individuals in the U.S. have ostomies. The American Cancer Society estimates 43,030 rectal cancer cases and 81,190 bladder cancer cases will be diagnosed in 2018.Of these, at least 30,000 will receive ostomies, and an additional unknown number due to gynecologic, other gastrointestinal, or other gastro-urinary tumors. The health-related quality of life impact is tremendous and greater than with many other cancer treatments. An ostomy is often a prolonged or lifelong disabling problem for cancer survivors. The adaptation period is quite variable. In our R01 study, 18% of participants took at least one year to be comfortable, or never felt comfortable, in managing their ostomy care. Importantly, many patients cannot attend in-person self-management programs or patient groups for a myriad of reasons, including distance to travel, lack of access to transportation, monetary outlays, competing demands (such as work), or comorbidities making travel difficult. In addition, a national shortage of OCNs means patients with an ostomy, whether newly placed or a long-term issue, receive little help. It is imperative to study interventions for rural survivors aimed to limit family financial burdens, improve ostomy outcomes, and improve survivors' well-being.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.
Vuyyuru SK, Ma C, Sharma T, Nguyen TM, et al · · 2024 · cited 3× · PMID 38135729 · DOI 10.1093/ibd/izad293

Verify or expand the search:

Other recruiting trials for Ostomy

Currently open trials in the same condition.

NCT06826404 — High-fidelity Simulators and Standardized Patients on the Stoma Care · NA · active not recruiting
NCT06583577 — Ostomy Simulation for Patient Education Prior to Urologic Bowel Diversion Surgeries · NA · recruiting
NCT06310070 — 3D Printed Personalized Ostomy Appliance · NA · recruiting
NCT06213441 — Improving the Quality of Life and Self-sufficiency of Individuals With Stoma: Pecha Kucha Training Via Smartphone · NA · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03913715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 11 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing